Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Ceftazidime-avibactam

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Selected DailyMed label (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Avycaz ® (ceftazidime-Avibactam) (opens in a new tab)Original source URL: https://globalrph.com/dilution/avycaz-ceftazidime-and-avibactam/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/avycaz-ceftazidime-and-avibactam/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:44:55.402970+00:00
Source location
div.post-content
Packaged content SHA-256
0111ee3c664c000091557ad1b9d5ec5bf27f0876add11916e7f1fbbfbc848ed5
Original response SHA-256
4298438102d8b8587e4ce5aef1272142e5b511fbb0371a633e68334f417a06d1
Source body SHA-256
578e93f0e3f318f89facc399a4e02452c56ef61c4412d242f31309ca786a5392

IV Dilution - AVYCAZ (ceftazidime and avibactam) for injection
[ Usual Diluents ] [ Standard Dilution ] [ Storage and Stability ]
DESCRIPTION CLINICAL PHARMACOLOGY INDICATIONS AND USAGE
CONTRAINDICATIONS PRECAUTIONS ADVERSE REACTIONS
DOSAGE AND ADMINISTRATION HOW SUPPLIED WARNINGS
PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information / PDF]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS, D5W

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] Return to article top

[2.5 grams] [50 - 250 ml] [120 minutes]
(ceftazidime 2 gram and avibactam 0.5 grams)

Renal:
[1.25 grams] [50 - 250 ml] [120 minutes]
[0.94 grams] [50 - 250 ml] [120 minutes]

Separate renal reference: Open Renal Dosing Master (opens in a new tab)

AVYCAZ is supplied as a dry powder, which must be constituted and subsequently diluted, using aseptic technique prior to intravenous infusion.

  1. Constitute the powder in the AVYCAZ vial with 10 mL of one of the following solutions:
    • sterile water for injection, USP
    • 0.9% of sodium chloride injection, USP (normal saline)
    • 5% of dextrose injection, USP
    • all combinations of dextrose injection and sodium chloride injection, USP, containing up to 2.5% dextrose, USP, and 0.45% sodium chloride, USP, or
    • lactated Ringer's injection, USP
  2. Mix gently. The constituted AVYCAZ solution will have an approximate ceftazidime concentration of 0.167 grams/mL and an approximate avibactam concentration of 0.042 grams/mL. The final volume is approximately 12 mL. The constituted solution is not for direct injection. The constituted solution must be diluted before intravenous infusion.
  1. Prepare the required dose for intravenous infusion by withdrawing the appropriate volume determined from Table 3 from the constituted vial.
    Table 3. Preparation of AVYCAZ Doses
    AVYCAZ (ceftazidime and avibactam) Dose Volume to Withdraw from Constituted Vial for Further Dilution to 50 to 250 mL
    2.5 grams (2 grams and 0.5 grams) 12 mL (entire contents)
    1.25 grams (1 gram and 0.25 grams) 6 mL
    0.94 grams (0.75 grams and 0.19 grams) 4.5 mL
  2. Before infusion, dilute the withdrawn volume of the constituted AVYCAZ solution further with the same diluent used for constitution of the powder (except sterile water for injection), to achieve a total volume between 50 mL (ceftazidime 0.04 grams/mL and avibactam 0.01 grams/mL) to 250 mL (ceftazidime 0.008 grams/mL and avibactam 0.002 grams/mL) in an infusion bag. If sterile water for injection was used for constitution, use any of the other appropriate constitution diluents for dilution.
  3. Mix gently and ensure that the contents are dissolved completely. Visually inspect the diluted AVYCAZ solution (for administration) for particulate matter and discoloration prior to administration (the color of the AVYCAZ infusion solution for administration ranges from clear to light yellow).
  4. Use the diluted AVYCAZ solution in the infusion bags within 12 hours when stored at room temperature.
  5. The diluted AVYCAZ solution in the infusion bags may be stored under refrigeration at 2 to 8°C (36 to 46°F) up to 24 hours following dilution and used within 12 hours of subsequent storage at room temperature.

Stability data:
Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
Following dilution of the constituted solutions with the appropriate diluents, AVYCAZ solutions in the infusion bags may also be refrigerated at 2 to 8°C (36 to 46°F) for up to 24 hours; and then should be used within 12 hours of subsequent storage at room temperature. Following dilution of the constituted solutions with the appropriate diluents, AVYCAZ solutions in the infusion bags are stable for 12 hours when stored at room temperature.

Upon constitution with appropriate diluent, the constituted AVYCAZ solution may be held for no longer than 30 minutes prior to transfer and dilution in a suitable infusion bag.

WARNINGS Return to article top

See warnings and precautions below.

DESCRIPTION Return to article top

Description:
AVYCAZ is an antibacterial combination product consisting of the semisynthetic cephalosporin ceftazidime pentahydrate and the beta-lactamase inhibitor avibactam sodium for intravenous administration.

Ceftazidime
Ceftazidime is a semisynthetic, beta-lactam antibacterial drug. It is the pentahydrate of (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate. Its molecular weight is 636.6. The empirical formula is C22 H32 N6 O12 S2.

Avibactam
Avibactam sodium chemical name is sodium [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] sulfate. Its molecular weight is 287.23. The empirical formula is C7 H10 N3 O6 SNa.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

The ceftazidime component of AVYCAZ is a cephalosporin antibacterial drug with in vitro activity against certain gram-negative and gram-positive bacteria. The bactericidal action of ceftazidime is mediated through binding to essential penicillin-binding proteins (PBPs). The avibactam component of AVYCAZ is a non-beta-lactam beta-lactamase inhibitor that inactivates some beta-lactamases and protects ceftazidime from degradation by certain beta-lactamases. Avibactam does not decrease the activity of ceftazidime against ceftazidime-susceptible organisms.

AVYCAZ demonstrated in vitro activity against Enterobacteriaceae in the presence of some beta-lactamases and extended-spectrum beta-lactamases (ESBLs) of the following groups: TEM, SHV, CTX-M, Klebsiella pneumoniae carbapenemase (KPCs), AmpC, and certain oxacillinases (OXA). AVYCAZ also demonstrated in vitro activity against P. aeruginosa in the presence of some AmpC beta-lactamases, and certain strains lacking outer membrane porin (OprD). AVYCAZ is not active against bacteria that produce metallo-beta lactamases and may not have activity against gram-negative bacteria that overexpress efflux pumps or have porin mutations.

Resistance
No cross-resistance with other classes of antimicrobials has been identified. Some isolates resistant to other cephalosporins (including ceftazidime) and to carbapenems may be susceptible to AVYCAZ.

Interaction with Other Antimicrobials
In vitro studies have not demonstrated antagonism between AVYCAZ and colistin, levofloxacin, linezolid, metronidazole, tigecycline, tobramycin, or vancomycin.

Activity against Ceftazidime-Nonsusceptible Bacteria in Animal Infection Models

Avibactam restored activity of ceftazidime in animal models of infection (e.g. thigh infection, pyelonephritis, systemic infection induced by intraperitoneal injection) caused by ceftazidime non-susceptible beta-lactamase- producing (e.g., ESBL, KPC and AmpC) gram-negative bacteria.

Antimicrobial Activity
AVYCAZ has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections

INDICATIONS AND USAGE Return to article top

AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms:

Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole (1.1)
Complicated Urinary Tract Infections (cUTI), including Pyelonephritis (1.2)

In the treatment of cUTI, as only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients with cUTI who have limited or no alternative treatment options (1.1, 1.2)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.3)

CONTRAINDICATIONS Return to article top

Contraindications:
AVYCAZ is contraindicated in patients with known serious hypersensitivity to the components of AVYCAZ (ceftazidime and avibactam), avibactam-containing products, or other members of the cephalosporin class

PRECAUTIONS Return to article top

WARNINGS AND PRECAUTIONS:

Decreased efficacy in patients with baseline CrCl of 30 to less than or equal to 50 mL/ min. Monitor CrCl at least daily in patients with changing renal function and adjust the dose of AVYCAZ accordingly. (5.1)
Hypersensitivity reactions: Includes anaphylaxis and serious skin reactions. Cross-hypersensitivity may occur in patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue AVYCAZ. (5.2)
Clostridium difficile-associated diarrhea: Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including AVYCAZ. Evaluate if diarrhea occurs. (5.3)
Central Nervous System Reactions: Seizures and other neurologic events may occur, especially in patients with renal impairment. Adjust dose in patients with renal impairment. (5.4)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

The most common adverse reactions in cIAI (>=/ 5%, when used with metronidazole) are diarrhea, nausea and vomiting. In cUTI, the most common adverse reactions (>=10%) are constipation and anxiety. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, LLC, at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 6/2016

See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide.

DOSAGE AND ADMINISTRATION Return to article top

2.1 Recommended Dosage

The recommended dosage of AVYCAZ is 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) administered every 8 hours by intravenous (IV) infusion over 2 hours in patients 18 years of age and older in patients with normal renal function. For treatment of cIAI, metronidazole should be given concurrently. The guidelines for dosage of AVYCAZ in patients with creatinine clearance [CrCl] greater than 50 mL/min are listed in Table 1.

Table 1. Dosage of AVYCAZ 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) by Indication
Infection Dosage Frequency Infusion Time
(hours) 		Duration of Treatment
Complicated Intra-abdominal Infections [used in combination with metronidazole] 2.5 grams Every 8 hours 2 5 to 14 days
Complicated Urinary Tract Infections including Pyelonephritis 2.5 grams Every 8 hours 2 7 to 14 days

2.2 Dosage Adjustments in Patients with Renal Impairment

Separate renal reference: Open Renal Dosing Master (opens in a new tab)

The recommended AVYCAZ dosage in patients with varying degrees of renal function is presented in Table 2. For patients with changing renal function, monitor CrCl at least daily and adjust the dosage of AVYCAZ accordingly [see Warnings and Precautions (5.1), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Table 2. Dosage of AVYCAZ in Patients with Renal Impairment
Estimated Creatinine Clearance (mL/minute) aSeparate renal reference: Open Renal Dosing Master (opens in a new tab) Recommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam)b
31 to 50 AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) intravenously every 8 hours
16 to 30 AVYCAZ 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously every 12 hours
6 to 15 c AVYCAZ 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously every 24 hours
Less than or equal to 5 c AVYCAZ 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously every 48 hours

a As calculated using the Cockcroft-Gault formula.

b All doses of AVYCAZ are administered over 2 hours

c Both ceftazidime and avibactam are hemodialyzable; thus, administer AVYCAZ after hemodialysis on hemodialysis days.

2.3 Preparation of the AVYCAZ Solution for Administration

AVYCAZ is supplied as a dry powder, which must be constituted and subsequently diluted, using aseptic technique prior to intravenous infusion.

  1. Constitute the powder in the AVYCAZ vial with 10 mL of one of the following solutions:
    • sterile water for injection, USP
    • 0.9% of sodium chloride injection, USP (normal saline)
    • 5% of dextrose injection, USP
    • all combinations of dextrose injection and sodium chloride injection, USP, containing up to 2.5% dextrose, USP, and 0.45% sodium chloride, USP, or
    • lactated Ringer's injection, USP
  2. Mix gently. The constituted AVYCAZ solution will have an approximate ceftazidime concentration of 0.167 grams/mL and an approximate avibactam concentration of 0.042 grams/mL. The final volume is approximately 12 mL. The constituted solution is not for direct injection. The constituted solution must be diluted before intravenous infusion.
  1. Prepare the required dose for intravenous infusion by withdrawing the appropriate volume determined from Table 3 from the constituted vial.
    Table 3. Preparation of AVYCAZ Doses
    AVYCAZ (ceftazidime and avibactam) Dose Volume to Withdraw from Constituted Vial for Further Dilution to 50 to 250 mL
    2.5 grams (2 grams and 0.5 grams) 12 mL (entire contents)
    1.25 grams (1 gram and 0.25 grams) 6 mL
    0.94 grams (0.75 grams and 0.19 grams) 4.5 mL
  2. Before infusion, dilute the withdrawn volume of the constituted AVYCAZ solution further with the same diluent used for constitution of the powder (except sterile water for injection), to achieve a total volume between 50 mL (ceftazidime 0.04 grams/mL and avibactam 0.01 grams/mL) to 250 mL (ceftazidime 0.008 grams/mL and avibactam 0.002 grams/mL) in an infusion bag. If sterile water for injection was used for constitution, use any of the other appropriate constitution diluents for dilution.
  3. Mix gently and ensure that the contents are dissolved completely. Visually inspect the diluted AVYCAZ solution (for administration) for particulate matter and discoloration prior to administration (the color of the AVYCAZ infusion solution for administration ranges from clear to light yellow).
  4. Use the diluted AVYCAZ solution in the infusion bags within 12 hours when stored at room temperature.
  5. The diluted AVYCAZ solution in the infusion bags may be stored under refrigeration at 2 to 8°C (36 to 46°F) up to 24 hours following dilution and used within 12 hours of subsequent storage at room temperature.

2.4 Drug Compatibility

The AVYCAZ solution for administration at the range of diluted concentrations of ceftazidime 0.008 g/mL and avibactam 0.002 g/mL to ceftazidime 0.04 g/mL and avibactam 0.01 g/mL is compatible with the more commonly used intravenous infusion fluids in infusion bags (including Baxter® Mini-Bag Plus™) such as:

  • 0.9% sodium chloride injection, USP
  • 5% dextrose injection, USP
  • all combinations of dextrose injection and sodium chloride injection, USP, containing up to 2.5% dextrose, USP, and 0.45% sodium chloride, USP
  • lactated ringer's injection, USP, and
  • Baxter® Mini-Bag Plus™ containing 0.9% sodium chloride injection or 5% dextrose injection.

Compatibility of AVYCAZ solution for administration with other drugs has not been established.

2.5 Storage of Constituted Solutions

Upon constitution with appropriate diluent, the constituted AVYCAZ solution may be held for no longer than 30 minutes prior to transfer and dilution in a suitable infusion bag.

Following dilution of the constituted solutions with the appropriate diluents, AVYCAZ solutions in the infusion bags are stable for 12 hours when stored at room temperature.

Following dilution of the constituted solutions with the appropriate diluents, AVYCAZ solutions in the infusion bags may also be refrigerated at 2 to 8°C (36 to 46°F) for up to 24 hours; and then should be used within 12 hours of subsequent storage at room temperature.

HOW SUPPLIED Return to article top

DOSAGE FORMS AND STRENGTHS:
AVYCAZ 2.5 grams (ceftazidime and avibactam) for injection is supplied in single-dose, clear glass vial containing: ceftazidime 2 grams (equivalent to 2.635 grams of ceftazidime pentahydrate/sodium carbonate) and avibactam 0.5 grams (equivalent to 0.551 grams of avibactam sodium). Vials are supplied as individual vial (NDC# 0456-2700-01) and in cartons containing 10 vials (NDC# 0456-2700-10)

Storage and Stability Return to article top

AVYCAZ vials should be stored at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature]. Protect from light. Store in carton until time of use.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • A retrieved source document is available; clinical reconciliation and a second-source claim map remain incomplete
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
adjustment_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      • Source kind
        label_snapshot
        Local pointer
        /mechanism_summary
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Concise GlobalRPh summary reviewed against the selected DailyMed label clinical-pharmacology or microbiology content.
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ceftazidime-avibactam
      Source IDH51-C5B3086502B454F999C5689E
      Generic name
      Ceftazidime-avibactam
      Source IDH51-9746F805A4A248FFFD4D03CB
      Class
      Antibacterial
      Source IDH51-8CA8E1C44449805A00A92403
      Subclass
      Third-generation cephalosporin plus beta-lactamase inhibitor
      Source IDH51-9E720BEDBCF63DBA91BCC7FA
      Primary uses
      1. Complicated intra-abdominal infection with metronidazole
        Source IDH51-F8B3D7B6371DA13BB3148AD7
      2. Complicated urinary infection
        Source IDH51-A4636A5205B9CD685839D09B
      3. Hospital-acquired and ventilator-associated pneumonia
        Source IDH51-E424F831DE14295BE48E538D
      Mechanism
      The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms.
      Source IDH51-E2016618B0FF307638486015
      Mechanism level
      class_level
      Source IDH51-86BE0A26BB5A575724FF266C
      Basic dosing orientation
      Adult | Existing preparation record; use current package insert for indication-specific selection | Common label dose 2.5 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric age 3 months and older | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
      Source IDH51-0614849F1C3DD0229562B6C6
      Administration orientation
      Infuse over 2 hours
      Source IDH51-D32F791CF88C8A4E0C7E49B7
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-DE0A64EC6A5CE37D67E70E4A
      Key safety orientation
      1. Serious beta-lactam hypersensitivity.
        Source IDH51-F40D1C3EBBDEEDB43E95EC83
      2. Dose adjustment errors during rapidly changing renal function may cause under- or overexposure.
        Source IDH51-809408D877068707EEA59E24
      Coverage path
      structured_local_snapshot
      Source IDH51-D23EA8F264711D04C5AB6E03
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-4318E48368C713CCAACB0789
      Legacy title
      Ceftazidime-avibactam (Avycaz)
      Source IDH51-D1368A16527D73AE75FCDECC
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-930ADBEB2C671B5BC1531874
      Search text
      Ceftazidime-avibactam Antibacterial Third-generation cephalosporin plus beta-lactamase inhibitor Complicated intra-abdominal infection with metronidazole Complicated urinary infection Hospital-acquired and ventilator-associated pneumonia The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms. Adult | Existing preparation record; use current package insert for indication-specific selection | Common label dose 2.5 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric age 3 months and older | Existing preparation record; use current package insert for indication-specific selection | Weight-based dose | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Infuse over 2 hours Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. Serious beta-lactam hypersensitivity. Dose adjustment errors during rapidly changing renal function may cause under- or overexposure. Structured GlobalRPh route snapshot AVYCAZ AVYCAZ (ceftazidime and avibactam) powder for solution DailyMed label snapshot dosage administration dosage forms strengths mechanism
      Source IDH51-E4D865A47C28C5C87BFDDCFB
      Official access mode
      direct_label
      Source IDH51-E79D711A5997C47C693A75DD
      Official search query
      Ceftazidime-avibactam
      Source IDH51-47B87B7F5870768D09EC6FDB
      Official access reason
      Very-high-confidence exact IV product label selected during the v5.1 build-time review. Open the current full DailyMed monograph and verify the stocked product before use.
      Source IDH51-314220AA3BA4E69A153E6207
      Label snapshot available
      true
      Source IDH51-4762306AB422FE3CE9B44348
      Label snapshot setid
      d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
      Source IDH51-99FFB4E24B15FE652051CF6B

      No separate structured rows were bundled for IV push, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-85BF233673E3E4987975A51A
      Adult
      Source IDH51-D48B32C8EE67FC9D154E08C9
      		Common label dose 2.5 g
      Source IDH51-4A451ED70C9BD20D65DB4ADE
      		Reconstitute vial with 10 mL Sterile Water for Injection, NS, or D5W as current label permits, then withdraw entire contents.
      Source IDH51-E102C2983DC07F70AE6918C2
      		NS, D5W, or other label-compatible solution
      Source IDH51-C84F69FA01F3276A7BC2AE53
      		50 to 250 mL
      Source IDH51-865CB1156DE47C5ABC8B5CD6
      		Within label concentration range
      Source IDH51-995EDE44C8CFDC163EEFBD03
      		Infuse over 2 hours
      Source IDH51-614E22A7CECDE3432631CDC0
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-CFA37C3F285EFA399A6F4527
      		Renal function should be monitored at least daily when changing.
      Source IDH51-74C36E77AA7E9201471774CC
      Source IDH51-8B0B43EBB6A6F4DDC8721AC9
      Pediatric age 3 months and older
      Source IDH51-A3005E08265FBA6F08C848E4
      		Weight-based dose
      Source IDH51-871B7347C085B484457E975E
      		Reconstitute per label.
      Source IDH51-8D4E678F5E6BED2CB3F14830
      		Compatible fluid
      Source IDH51-A319EAF8ABD42DD71C992B70
      		Weight-appropriate volume
      Source IDH51-41D55532395E30CADBE8E591
      		Within label range
      Source IDH51-FF5D6A2B5DD8ED22DB842DAE
      		Infuse over 2 hours
      Source IDH51-A4CDE7B10265D7DB878F6BCE
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-3C572AAE42AFD8985BFDF896

      Historical DailyMed label snapshot

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ceftazidime-avibactam
      Source IDH51-E36A54DB63F6530AC904ACD6
      Catalog name
      Ceftazidime-avibactam
      Source IDH51-47FCB61F8B3FC7D219B57550
      Selection status
      accepted_high_confidence
      Source IDH51-53A3F7B28E7D59078B5B814A
      Confidence
      very_high
      Source IDH51-8F17801E0384F0DA7AFFC938
      Match path
      search_to_exact_label
      Source IDH51-B91035D3384D93A164CFBED1
      Brand name
      AVYCAZ
      Source IDH51-F73CA86CD9A525FA1956A29A
      Label title
      AVYCAZ (ceftazidime and avibactam) powder for solution
      Source IDH51-BEDC05944DAC2F88D6AD061C
      Setid
      d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd
      Source IDH51-2857EF1605994528BCBD54FA
      Route
      Intermittent intravenous infusion
      Source IDH51-6B697A2142CD199E7213CC89
      Dosage form
      Combination powder for reconstitution and further dilution
      Source IDH51-AF7AFEFB6C11636CB0589480
      Dosage administration summary
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. A common adult regimen with creatinine clearance above 50 mL/min is 2.5 g every 8 hours infused over 2 hours; indication, age, and renal function can change the regimen.
        Source IDH51-01979DBE31D246FAF37E7010
      2. Reconstitute the vial and further dilute the withdrawn dose in a compatible infusion container according to the current label.
        Source IDH51-13FC9EBD5C2FD40FD757E5FF
      3. Use the exact renal-function method and current pediatric or renal table before selecting a dose or interval.
        Source IDH51-6765CB9C20AD228154CE5B35
      Dosage forms strengths
      1. 2.5 g single-dose vial containing 2 g ceftazidime and 0.5 g avibactam
        Source IDH51-4E1C2C871E8C2DCDE4E3A835
      Mechanism summary
      Ceftazidime inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins; avibactam inhibits selected beta-lactamases and protects ceftazidime from hydrolysis.
      Source IDH51-28FEE6D79C22E403A65106F6
      Scope note
      Selected AVYCAZ combination label. Do not apply this summary to ceftazidime alone or to another beta-lactam/beta-lactamase-inhibitor product.
      Source IDH51-62481C01E1861E0E8A3E46BC
      Reviewed on
      2026-08-31
      Source IDH51-A6C29CA1B4D098851AD94919
      Mechanism source
      Concise GlobalRPh summary reviewed against the selected DailyMed label clinical-pharmacology or microbiology content.
      Source IDH51-AB6767B558FA596904AC3061
      Source sections
      1. Dosage and Administration
        Source IDH51-753ABA25BE8DFC63D4E8B46A
      2. Dosage Forms and Strengths
        Source IDH51-6DBCB8122E1F10B1E32C4040
      3. Clinical Pharmacology or Microbiology as applicable
        Source IDH51-0323F21ABDC899BF6F8D5CE3
      Retrieval method
      Manual build-time review of the current DailyMed full prescribing information for the selected Set ID; no live server retrieval is required during page use.
      Source IDH51-A86DF15DD848AFFA7E2D93F0
      Label status
      current
      Source IDH51-576A138322D4159DDD5127A0
      Disclaimer
      Verify the exact formulation, strength, manufacturer, NDC, route, current label revision, patient-specific order, institutional policy, and monitoring before use.
      Source IDH51-0A8D98EB1CD1049B045549A5

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-F41D49C7378A0DCE18B39311
      IV infusion
      Source IDH51-57E7B643119299876A3415BB
      		Adult
      Source IDH51-A5AFF37AEBDA56B4AF300B01
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-D98317D728FE33CD5C875547
      		Common label dose 2.5 g
      Source IDH51-11E23D0DB1AA600DDAF1FA84
      		Not normalized in the preparation record
      Source IDH51-A7924DBE07479CFB6C0781C5
      		See current package insert and professional guidance
      Source IDH51-F006DC0DBD1626D85D277267
      		Infuse over 2 hours
      Source IDH51-C83A9DBCDD8AD28A2100F1DB
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-1C8E3CAE3E779066E4029B04
      		Renal function should be monitored at least daily when changing.
      Source IDH51-469580D6C9A6F2382AD8BEDC
      Source IDH51-D7EA3925ECFF23EF7945AAC9
      IV infusion
      Source IDH51-AA40B872338ECD44F7957156
      		Pediatric age 3 months and older
      Source IDH51-FF01FB92EB3B7E32741317E6
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-258364E9987A727FFB2A62C2
      		Weight-based dose
      Source IDH51-1F41591CED2BC90C3AC60D0A
      		Not normalized in the preparation record
      Source IDH51-96F38F65609BA8858272FE57
      		See current package insert and professional guidance
      Source IDH51-51FF43EA3EAD6B098091D28F
      		Infuse over 2 hours
      Source IDH51-8D5CBC7E2E276DC793943287
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-F0FCA873088814C3EC65029B

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      adjustment_required
      Source IDH51-2AFCC6EB5199365575A313D4
      Summary
      Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-2970549E28C8FD65B8409346
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-E98F5755125724B2EAF4448E

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Complicated intra-abdominal infection with metronidazole
        Source IDH51-9B1F7AE70556583C5E25DC4F
      2. Complicated urinary infection
        Source IDH51-3CCA05EBA7C70FF0E5559F66
      3. Hospital-acquired and ventilator-associated pneumonia
        Source IDH51-8287E9910D3A3C80E6DF14D5

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Serious beta-lactam hypersensitivity.
        Source IDH51-3F4FB6B8256E3BC6432C112D
      2. Dose adjustment errors during rapidly changing renal function may cause under- or overexposure.
        Source IDH51-1D652EFB4FE2072A4D3836D3

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Renal function
        Source IDH51-0E68D353DCA0DBBD1C5E27A1
      2. Clinical and microbiologic response
        Source IDH51-DF318F10214AA62D7C65409F
      3. Neurologic status
        Source IDH51-C7BDF0420D8767B668234C13

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-EE2C65FD78D7EB7EC4EF7766
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-A6EDA21B0F1E750465793F5D
      		https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-299ECCF9C81686EC27AFE17D
      		Professional institutional guidance
      Source IDH51-1A8357639183635723E27729
      Source IDH51-627E0151BFD59DC335CC73E0
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-91F1C49E55DEA95BEA692D9E
      		https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-D0E6C597E75CEFA44A776BA8
      		Professional institutional guidance
      Source IDH51-1C2E3001CB29DFC6B555803A
      Source IDH51-0162941D5DA18B68EB28FC3C
      UCSF pediatric antimicrobial dosing
      Source IDH51-575AFD8C94A92B49034F591E
      		https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-33229361429B8ED7F1D09387
      		Professional institutional guidance
      Source IDH51-DD36FAF8665B71B6A7B917CA
      Source IDH51-B539E2ACEACABF0E140B1E44
      UCSF neonatal antimicrobial dosing
      Source IDH51-F09E3A4FBE52F6292D2E49DE
      		https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-4A7CF0951ED57BA40737746E
      		Professional institutional guidance
      Source IDH51-452EF73E1C65226E3D5513C4
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      ceftazidime-avibactam
      Source IDH51-26BEBB48066634A63C2D224D
      Generic name
      Ceftazidime-avibactam
      Source IDH51-45A73821E20CABEFDD5A0DBF
      Brand names
      1. Avycaz
        Source IDH51-19FB751D59BC22DCF57E8970
      Class
      Antibacterial
      Source IDH51-0E54C670CDFAB181F1E15635
      Subclass
      Third-generation cephalosporin plus beta-lactamase inhibitor
      Source IDH51-8AB739EDDC5467AC4BCCF9B3
      Summary
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Fixed 4:1 ceftazidime-to-avibactam product administered by two-hour infusion with age- and renal-function-specific dosing.
      Source IDH51-C1FA44C80C6B9DC36860B16C
      Populations
      1. Adult
        Source IDH51-AA6579C6C5B231A2692DE911
      2. Pediatric
        Source IDH51-B8BE4AA0BB0FF448764D7A23
      Evidence tier
      Enhanced current-label framework
      Source IDH51-A00C2E97BCC683C37075D132
      High alert
      false
      Source IDH51-5FF8EAEE13D55AC785D5BFC3
      Hazardous
      false
      Source IDH51-84744A4D1542B76626936DCF
      Status
      Active
      Source IDH51-33CAC322FE21FF7AA4FE6439
      Reviewed
      2026-08-29
      Source IDH51-2B20A62F808313905300A906
      Version added
      1.2
      Source IDH51-C0D69237EBC05D36E1446CC9
      Sources
      LabelUrlKind
      Source IDH51-56C74FF5793E5E5F5D672533
      DailyMed label search
      Source IDH51-50FD167625A43AA196A0602F
      		https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ceftazidime-avibactam (opens in a new tab)
      Source IDH51-ED72752A727728A075CE3C80
      		Primary
      Source IDH51-39657979BD24784710193746
      Source IDH51-D9AC7F4756D9BC5D6400D59C
      GlobalRPh legacy IV dilution monograph
      Source IDH51-E2A0EA78337E6FD1C5EFF256
      		legacy:auto
      Source IDH51-4B1AF2E47999FD452196BCFD
      		Legacy
      Source IDH51-E0C9E18C07B14B644B41FD7A
      Legacy title
      Ceftazidime-avibactam (Avycaz)
      Source IDH51-DB0209C8488F2F7CDD044DF1
      Clinical release verification
      Audit version
      3.4
      Source IDH51-8680DAA8F327BA9882E2C568
      Audited on
      2026-08-30
      Source IDH51-8291F618EB2B852C43C67C5D
      Level
      amber
      Source IDH51-61B15A763662F56CFEB9110A
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-A0D9D5A4863A9AFBAEC5D709
      Exact current label candidate
      false
      Source IDH51-12CFFED663E162E3E25CC225
      Numeric support ratio
      0
      Source IDH51-AD8698550F16F6566B301BD5
      Reference url count
      5
      Source IDH51-4FF892F8D47F7D74635126D4
      Broken reference count
      0
      Source IDH51-AAD774AF1195CC0ACD1B5636
      Point of use confirmation required
      true
      Source IDH51-12877809C7656E10817477F6
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-214F98CB88113107EFBBF7FA
      Version updated
      5.1
      Source IDH51-6AAA97E46D2D4502DF8F4E73

      Dosing source fields

      Id
      ceftazidime-avibactam
      Source IDH51-245671801F2EAD459097A03B
      Generic name
      Ceftazidime-avibactam
      Source IDH51-9D2959A98213BA573270C9DA
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-497D22BB2E0434A9DA56FC7F
      Package insert
      Query name
      Ceftazidime-avibactam
      Source IDH51-761A5E9332DB2FABE4473A2A
      Product and route must match
      true
      Source IDH51-877BDCACAAA38E3CCF366A23
      Live current label enabled
      false
      Source IDH51-A0588D46498E862DDF482E32
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-53B75814CD930EECFB090F3C
      Direct official label access enabled
      true
      Source IDH51-9852E9B2CD4C041D7941CEFB
      Outbound server request required
      false
      Source IDH51-2F32797CFBFBE0DBD3EF3D94
      Local summary status
      not_bundled
      Source IDH51-A66D8274B5FC62E9C1AC9246
      Clinical review
      Locally normalized
      false
      Source IDH51-99160DB021B6A7C95C0DDDEC
      Reviewed
      2026-08-29
      Source IDH51-23E9306350202BBDE6C0745C
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-B3E0B3D2394C03EA87BD7A3D
      Clinical release verification
      Audit version
      3.4
      Source IDH51-F14453174A20417F12C43270
      Audited on
      2026-08-30
      Source IDH51-6B7540BC1341F2B38CB94FCB
      Level
      amber
      Source IDH51-DF6BF12930DC10D19BEBB5A4
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-AE78D69CF73386E526694814
      Exact current label candidate
      false
      Source IDH51-1DCD7B887B493FDDF742269A
      Numeric support ratio
      0
      Source IDH51-4AB7588CB26D6F5D3A09D530
      Reference url count
      5
      Source IDH51-736261C34403B26F032998C7
      Broken reference count
      0
      Source IDH51-AF5E5783BA3E217493226611
      Point of use confirmation required
      true
      Source IDH51-420FCCB5672C797DDFF1CD61
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-26B47639F251C70C236AB5B0
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      ceftazidime-avibactam
      Source IDH51-FD31CF11C00BFC45BB8011CE
      Name
      Ceftazidime-avibactam
      Source IDH51-1BC1B33421306CF6FAA44FF0
      Brands
      Avycaz
      Source IDH51-14001F3B5B36B7CF80AC565E
      Therapeutic class
      Antibacterial
      Source IDH51-FBFE271C7AD924F85449358D
      Review version
      3.1
      Source IDH51-6CEA747604CDC020FE6EF575
      Review date
      2026-08-30
      Source IDH51-B5C1252B96BC9241E063EF0B
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-812A437E8AE4F9A0F1CE477A
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-E89D8DB0F1F29AC6930A0165
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-27800A122907A030F4FECBF6
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E3AA55ED612E5CF6647C4249
      Reconstitution concentration
      Reconstitute vial with 10 mL Sterile Water for Injection, NS, or D5W as current label permits, then withdraw entire contents. Reconstitute per label.
      Source IDH51-4B3954D72ED4BECBB2D08085
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-F40A85F5556681A468BE2718
      Appropriate standardized containers
      50 to 250 mL Weight-appropriate volume
      Source IDH51-D9606A8A290C6969F9DE841E
      Adult dosing range
      Common label dose 2.5 g Weight-based dose
      Source IDH51-9B2EA0A329303B0B8604F4B0
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-FEDDF3E4E6D8CD4743CE889A
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-F1FC3B0EC5664861BC331FE4
      Infusion time
      Infuse over 2 hours
      Source IDH51-191387BB1BBEDE1439A6CE73
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0426AAAA1B4E966766CE0372
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-4F7F2920AE895736C642B0E6
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-B534D7EF58CB37238E2C1445
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-7679480E9BC66EB0E3CB76F7
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-F4E3075A5ECC87DAEBCF08A3
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-BD0D3C206A9D6254BB7B2EEB
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-0586F7E6FAAB0CD8BF5158B5
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-7D6F54CFC0E4103578704B9A
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-74D0127A488242E5FE9212A2
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-75A5323A74EEF80BA16DC3C8
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-0C2F7762AD4E6BA8AC49EAF2
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-3C2840DE2632E0DA83B39383
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-B1B8F909B020000866BD7DAA
      Guide generation allowed
      true
      Source IDH51-CCFDBFC255822A6D4D099108
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-6B8B70037065A9C4435AC1FE
      Guide generation allowed
      false
      Source IDH51-7AFE525D41E419E66301D510
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-861D39044A12784CE35ECE2F
      Guide generation allowed
      false
      Source IDH51-8FA31FCCD455B96FDEEBCF73
      Route presence
      Structured dilution
      true
      Source IDH51-B158EDA72E2DD00474CA70C3
      Iv push
      false
      Source IDH51-D847FD59E0C134F61C94A7E5
      Continuous infusion
      false
      Source IDH51-CDD57C9ED22E33FAEC1E533C
      Pediatric source
      true
      Source IDH51-B78E2086E1775990FA4EEADE
      Neonatal source
      true
      Source IDH51-6B4B6C734A2B0A427B796974
      Legacy reference
      Status
      not_available
      Source IDH51-3D0BCBA7D724258E37F3E257
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-B4739B023A3657762AB149C9
      Source files
      1. catalog.json
        Source IDH51-CBA399F631FD123DC029028C
      2. dosing.json
        Source IDH51-733FD5C67AAB1BF06B826E4B
      3. legacy-map.json
        Source IDH51-D3B8978FCB38D3105EF4A8E2
      4. new-in-v1.2.json
        Source IDH51-5FAE7BE77E4355FB6874246B
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-2F0751AF30F1353CD318B214
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-26BEBB48066634A63C2D224Dcatalog.json
      /records/53/id      		Historical; current review incomplete
      H51-45A73821E20CABEFDD5A0DBFcatalog.json
      /records/53/generic_name      		Historical; current review incomplete
      H51-19FB751D59BC22DCF57E8970catalog.json
      /records/53/brand_names/0      		Historical; current review incomplete
      H51-0E54C670CDFAB181F1E15635catalog.json
      /records/53/class      		Historical; current review incomplete
      H51-8AB739EDDC5467AC4BCCF9B3catalog.json
      /records/53/subclass      		Historical; current review incomplete
      H51-C1FA44C80C6B9DC36860B16Ccatalog.json
      /records/53/summary      		Historical; current review incomplete
      H51-9B1F7AE70556583C5E25DC4Fcatalog.json
      /records/53/common_uses/0      		Historical; current review incomplete
      H51-3CCA05EBA7C70FF0E5559F66catalog.json
      /records/53/common_uses/1      		Historical; current review incomplete
      H51-8287E9910D3A3C80E6DF14D5catalog.json
      /records/53/common_uses/2      		Historical; current review incomplete
      H51-85BF233673E3E4987975A51Acatalog.json
      /records/53/preparations/0      		Historical; current review incomplete
      H51-D48B32C8EE67FC9D154E08C9catalog.json
      /records/53/preparations/0/population      		Historical; current review incomplete
      H51-4A451ED70C9BD20D65DB4ADEcatalog.json
      /records/53/preparations/0/amount      		Historical; current review incomplete
      H51-E102C2983DC07F70AE6918C2catalog.json
      /records/53/preparations/0/reconstitution      		Historical; current review incomplete
      H51-C84F69FA01F3276A7BC2AE53catalog.json
      /records/53/preparations/0/diluent      		Historical; current review incomplete
      H51-865CB1156DE47C5ABC8B5CD6catalog.json
      /records/53/preparations/0/final_volume      		Historical; current review incomplete
      H51-995EDE44C8CFDC163EEFBD03catalog.json
      /records/53/preparations/0/concentration      		Historical; current review incomplete
      H51-614E22A7CECDE3432631CDC0catalog.json
      /records/53/preparations/0/rate      		Historical; current review incomplete
      H51-CFA37C3F285EFA399A6F4527catalog.json
      /records/53/preparations/0/stability      		Historical; current review incomplete
      H51-74C36E77AA7E9201471774CCcatalog.json
      /records/53/preparations/0/notes      		Historical; current review incomplete
      H51-8B0B43EBB6A6F4DDC8721AC9catalog.json
      /records/53/preparations/1      		Historical; current review incomplete
      H51-A3005E08265FBA6F08C848E4catalog.json
      /records/53/preparations/1/population      		Historical; current review incomplete
      H51-871B7347C085B484457E975Ecatalog.json
      /records/53/preparations/1/amount      		Historical; current review incomplete
      H51-8D4E678F5E6BED2CB3F14830catalog.json
      /records/53/preparations/1/reconstitution      		Historical; current review incomplete
      H51-A319EAF8ABD42DD71C992B70catalog.json
      /records/53/preparations/1/diluent      		Historical; current review incomplete
      H51-41D55532395E30CADBE8E591catalog.json
      /records/53/preparations/1/final_volume      		Historical; current review incomplete
      H51-FF5D6A2B5DD8ED22DB842DAEcatalog.json
      /records/53/preparations/1/concentration      		Historical; current review incomplete
      H51-A4CDE7B10265D7DB878F6BCEcatalog.json
      /records/53/preparations/1/rate      		Historical; current review incomplete
      H51-3C572AAE42AFD8985BFDF896catalog.json
      /records/53/preparations/1/stability      		Historical; current review incomplete
      H51-4047A3BA10BA81B422F5D88Ccatalog.json
      /records/53/preparations/1/notes      		Historical; current review incomplete
      H51-3F4FB6B8256E3BC6432C112Dcatalog.json
      /records/53/warnings/0      		Historical; current review incomplete
      H51-1D652EFB4FE2072A4D3836D3catalog.json
      /records/53/warnings/1      		Historical; current review incomplete
      H51-0E68D353DCA0DBBD1C5E27A1catalog.json
      /records/53/monitoring/0      		Historical; current review incomplete
      H51-DF318F10214AA62D7C65409Fcatalog.json
      /records/53/monitoring/1      		Historical; current review incomplete
      H51-C7BDF0420D8767B668234C13catalog.json
      /records/53/monitoring/2      		Historical; current review incomplete
      H51-AA6579C6C5B231A2692DE911catalog.json
      /records/53/populations/0      		Historical; current review incomplete
      H51-B8BE4AA0BB0FF448764D7A23catalog.json
      /records/53/populations/1      		Historical; current review incomplete
      H51-A00C2E97BCC683C37075D132catalog.json
      /records/53/evidence_tier      		Historical; current review incomplete
      H51-5FF8EAEE13D55AC785D5BFC3catalog.json
      /records/53/high_alert      		Historical; current review incomplete
      H51-84744A4D1542B76626936DCFcatalog.json
      /records/53/hazardous      		Historical; current review incomplete
      H51-33CAC322FE21FF7AA4FE6439catalog.json
      /records/53/status      		Historical; current review incomplete
      H51-2B20A62F808313905300A906catalog.json
      /records/53/reviewed      		Historical; current review incomplete
      H51-C0D69237EBC05D36E1446CC9catalog.json
      /records/53/version_added      		Historical; current review incomplete
      H51-56C74FF5793E5E5F5D672533catalog.json
      /records/53/sources/0      		Historical; current review incomplete
      H51-50FD167625A43AA196A0602Fcatalog.json
      /records/53/sources/0/label      		Historical; current review incomplete
      H51-ED72752A727728A075CE3C80catalog.json
      /records/53/sources/0/url      		Historical; current review incomplete
      H51-39657979BD24784710193746catalog.json
      /records/53/sources/0/kind      		Historical; current review incomplete
      H51-D9AC7F4756D9BC5D6400D59Ccatalog.json
      /records/53/sources/1      		Historical; current review incomplete
      H51-E2A0EA78337E6FD1C5EFF256catalog.json
      /records/53/sources/1/label      		Historical; current review incomplete
      H51-4B1AF2E47999FD452196BCFDcatalog.json
      /records/53/sources/1/url      		Historical; current review incomplete
      H51-E0C9E18C07B14B644B41FD7Acatalog.json
      /records/53/sources/1/kind      		Historical; current review incomplete
      H51-DB0209C8488F2F7CDD044DF1catalog.json
      /records/53/legacy_title      		Historical; current review incomplete
      H51-8680DAA8F327BA9882E2C568catalog.json
      /records/53/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-8291F618EB2B852C43C67C5Dcatalog.json
      /records/53/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-61B15A763662F56CFEB9110Acatalog.json
      /records/53/clinical_release_verification/level      		Historical; current review incomplete
      H51-A0D9D5A4863A9AFBAEC5D709catalog.json
      /records/53/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-12CFFED663E162E3E25CC225catalog.json
      /records/53/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-92660A9D3839224BD6AA6410catalog.json
      /records/53/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-FEDA96B56B9D35D5811FE094catalog.json
      /records/53/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-AD8698550F16F6566B301BD5catalog.json
      /records/53/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-4FF892F8D47F7D74635126D4catalog.json
      /records/53/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-AAD774AF1195CC0ACD1B5636catalog.json
      /records/53/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-12877809C7656E10817477F6catalog.json
      /records/53/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-214F98CB88113107EFBBF7FAcatalog.json
      /records/53/clinical_release_verification/note      		Historical; current review incomplete
      H51-61FA4AE68A33946A1A5FEDF4catalog.json
      /records/53/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-6AAA97E46D2D4502DF8F4E73catalog.json
      /records/53/version_updated      		Historical; current review incomplete
      H51-E36A54DB63F6530AC904ACD6dailymed-label-snapshots-v5.1.json
      /records/16/id      		Historical; current review incomplete
      H51-47FCB61F8B3FC7D219B57550dailymed-label-snapshots-v5.1.json
      /records/16/catalog_name      		Historical; current review incomplete
      H51-53A3F7B28E7D59078B5B814Adailymed-label-snapshots-v5.1.json
      /records/16/selection_status      		Historical; current review incomplete
      H51-8F17801E0384F0DA7AFFC938dailymed-label-snapshots-v5.1.json
      /records/16/confidence      		Historical; current review incomplete
      H51-B91035D3384D93A164CFBED1dailymed-label-snapshots-v5.1.json
      /records/16/match_path      		Historical; current review incomplete
      H51-F73CA86CD9A525FA1956A29Adailymed-label-snapshots-v5.1.json
      /records/16/brand_name      		Historical; current review incomplete
      H51-BEDC05944DAC2F88D6AD061Cdailymed-label-snapshots-v5.1.json
      /records/16/label_title      		Historical; current review incomplete
      H51-2857EF1605994528BCBD54FAdailymed-label-snapshots-v5.1.json
      /records/16/setid      		Historical; current review incomplete
      H51-6B697A2142CD199E7213CC89dailymed-label-snapshots-v5.1.json
      /records/16/route      		Historical; current review incomplete
      H51-AF7AFEFB6C11636CB0589480dailymed-label-snapshots-v5.1.json
      /records/16/dosage_form      		Historical; current review incomplete
      H51-01979DBE31D246FAF37E7010dailymed-label-snapshots-v5.1.json
      /records/16/dosage_administration_summary/0      		Historical; current review incomplete
      H51-13FC9EBD5C2FD40FD757E5FFdailymed-label-snapshots-v5.1.json
      /records/16/dosage_administration_summary/1      		Historical; current review incomplete
      H51-6765CB9C20AD228154CE5B35dailymed-label-snapshots-v5.1.json
      /records/16/dosage_administration_summary/2      		Historical; current review incomplete
      H51-4E1C2C871E8C2DCDE4E3A835dailymed-label-snapshots-v5.1.json
      /records/16/dosage_forms_strengths/0      		Historical; current review incomplete
      H51-28FEE6D79C22E403A65106F6dailymed-label-snapshots-v5.1.json
      /records/16/mechanism_summary      		Historical; current review incomplete
      H51-62481C01E1861E0E8A3E46BCdailymed-label-snapshots-v5.1.json
      /records/16/scope_note      		Historical; current review incomplete
      H51-12037DF0D3EF2731EBF4C4F4dailymed-label-snapshots-v5.1.json
      /records/16/labeler      		Historical; current review incomplete
      H51-28FE76AF143085E467214C91dailymed-label-snapshots-v5.1.json
      /records/16/official_label_url      		Historical; current review incomplete
      H51-A6C29CA1B4D098851AD94919dailymed-label-snapshots-v5.1.json
      /records/16/reviewed_on      		Historical; current review incomplete
      H51-AB6767B558FA596904AC3061dailymed-label-snapshots-v5.1.json
      /records/16/mechanism_source      		Historical; current review incomplete
      H51-753ABA25BE8DFC63D4E8B46Adailymed-label-snapshots-v5.1.json
      /records/16/source_sections/0      		Historical; current review incomplete
      H51-6DBCB8122E1F10B1E32C4040dailymed-label-snapshots-v5.1.json
      /records/16/source_sections/1      		Historical; current review incomplete
      H51-0323F21ABDC899BF6F8D5CE3dailymed-label-snapshots-v5.1.json
      /records/16/source_sections/2      		Historical; current review incomplete
      H51-A86DF15DD848AFFA7E2D93F0dailymed-label-snapshots-v5.1.json
      /records/16/retrieval_method      		Historical; current review incomplete
      H51-576A138322D4159DDD5127A0dailymed-label-snapshots-v5.1.json
      /records/16/label_status      		Historical; current review incomplete
      H51-0A8D98EB1CD1049B045549A5dailymed-label-snapshots-v5.1.json
      /records/16/disclaimer      		Historical; current review incomplete
      H51-245671801F2EAD459097A03Bdosing.json
      /records/53/id      		Historical; current review incomplete
      H51-9D2959A98213BA573270C9DAdosing.json
      /records/53/generic_name      		Historical; current review incomplete
      H51-497D22BB2E0434A9DA56FC7Fdosing.json
      /records/53/coverage_status      		Historical; current review incomplete
      H51-761A5E9332DB2FABE4473A2Adosing.json
      /records/53/package_insert/query_name      		Historical; current review incomplete
      H51-9935905D2AA862F15ACFC84Fdosing.json
      /records/53/package_insert/preferred_setid      		Historical; current review incomplete
      H51-877BDCACAAA38E3CCF366A23dosing.json
      /records/53/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-A0588D46498E862DDF482E32dosing.json
      /records/53/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-53B75814CD930EECFB090F3Cdosing.json
      /records/53/package_insert/source_priority      		Historical; current review incomplete
      H51-9852E9B2CD4C041D7941CEFBdosing.json
      /records/53/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-2F32797CFBFBE0DBD3EF3D94dosing.json
      /records/53/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-A66D8274B5FC62E9C1AC9246dosing.json
      /records/53/package_insert/local_summary_status      		Historical; current review incomplete
      H51-2AFCC6EB5199365575A313D4dosing.json
      /records/53/renal/classification      		Historical; current review incomplete
      H51-2970549E28C8FD65B8409346dosing.json
      /records/53/renal/summary      		Historical; current review incomplete
      H51-E98F5755125724B2EAF4448Edosing.json
      /records/53/renal/method_note      		Historical; current review incomplete
      H51-F41D49C7378A0DCE18B39311dosing.json
      /records/53/existing_route_snapshots/0      		Historical; current review incomplete
      H51-57E7B643119299876A3415BBdosing.json
      /records/53/existing_route_snapshots/0/route      		Historical; current review incomplete
      H51-A5AFF37AEBDA56B4AF300B01dosing.json
      /records/53/existing_route_snapshots/0/population      		Historical; current review incomplete
      H51-D98317D728FE33CD5C875547dosing.json
      /records/53/existing_route_snapshots/0/indication      		Historical; current review incomplete
      H51-11E23D0DB1AA600DDAF1FA84dosing.json
      /records/53/existing_route_snapshots/0/dose      		Historical; current review incomplete
      H51-A7924DBE07479CFB6C0781C5dosing.json
      /records/53/existing_route_snapshots/0/interval      		Historical; current review incomplete
      H51-F006DC0DBD1626D85D277267dosing.json
      /records/53/existing_route_snapshots/0/duration      		Historical; current review incomplete
      H51-C83A9DBCDD8AD28A2100F1DBdosing.json
      /records/53/existing_route_snapshots/0/administration      		Historical; current review incomplete
      H51-1C8E3CAE3E779066E4029B04dosing.json
      /records/53/existing_route_snapshots/0/source_level      		Historical; current review incomplete
      H51-469580D6C9A6F2382AD8BEDCdosing.json
      /records/53/existing_route_snapshots/0/notes      		Historical; current review incomplete
      H51-D7EA3925ECFF23EF7945AAC9dosing.json
      /records/53/existing_route_snapshots/1      		Historical; current review incomplete
      H51-AA40B872338ECD44F7957156dosing.json
      /records/53/existing_route_snapshots/1/route      		Historical; current review incomplete
      H51-FF01FB92EB3B7E32741317E6dosing.json
      /records/53/existing_route_snapshots/1/population      		Historical; current review incomplete
      H51-258364E9987A727FFB2A62C2dosing.json
      /records/53/existing_route_snapshots/1/indication      		Historical; current review incomplete
      H51-1F41591CED2BC90C3AC60D0Adosing.json
      /records/53/existing_route_snapshots/1/dose      		Historical; current review incomplete
      H51-96F38F65609BA8858272FE57dosing.json
      /records/53/existing_route_snapshots/1/interval      		Historical; current review incomplete
      H51-51FF43EA3EAD6B098091D28Fdosing.json
      /records/53/existing_route_snapshots/1/duration      		Historical; current review incomplete
      H51-8D5CBC7E2E276DC793943287dosing.json
      /records/53/existing_route_snapshots/1/administration      		Historical; current review incomplete
      H51-F0FCA873088814C3EC65029Bdosing.json
      /records/53/existing_route_snapshots/1/source_level      		Historical; current review incomplete
      H51-BEC292E3C4B71CC3C6029F10dosing.json
      /records/53/existing_route_snapshots/1/notes      		Historical; current review incomplete
      H51-EE2C65FD78D7EB7EC4EF7766dosing.json
      /records/53/professional_sources/0      		Historical; current review incomplete
      H51-A6EDA21B0F1E750465793F5Ddosing.json
      /records/53/professional_sources/0/label      		Historical; current review incomplete
      H51-299ECCF9C81686EC27AFE17Ddosing.json
      /records/53/professional_sources/0/url      		Historical; current review incomplete
      H51-1A8357639183635723E27729dosing.json
      /records/53/professional_sources/0/kind      		Historical; current review incomplete
      H51-627E0151BFD59DC335CC73E0dosing.json
      /records/53/professional_sources/1      		Historical; current review incomplete
      H51-91F1C49E55DEA95BEA692D9Edosing.json
      /records/53/professional_sources/1/label      		Historical; current review incomplete
      H51-D0E6C597E75CEFA44A776BA8dosing.json
      /records/53/professional_sources/1/url      		Historical; current review incomplete
      H51-1C2E3001CB29DFC6B555803Adosing.json
      /records/53/professional_sources/1/kind      		Historical; current review incomplete
      H51-0162941D5DA18B68EB28FC3Cdosing.json
      /records/53/professional_sources/2      		Historical; current review incomplete
      H51-575AFD8C94A92B49034F591Edosing.json
      /records/53/professional_sources/2/label      		Historical; current review incomplete
      H51-33229361429B8ED7F1D09387dosing.json
      /records/53/professional_sources/2/url      		Historical; current review incomplete
      H51-DD36FAF8665B71B6A7B917CAdosing.json
      /records/53/professional_sources/2/kind      		Historical; current review incomplete
      H51-B539E2ACEACABF0E140B1E44dosing.json
      /records/53/professional_sources/3      		Historical; current review incomplete
      H51-F09E3A4FBE52F6292D2E49DEdosing.json
      /records/53/professional_sources/3/label      		Historical; current review incomplete
      H51-4A7CF0951ED57BA40737746Edosing.json
      /records/53/professional_sources/3/url      		Historical; current review incomplete
      H51-452EF73E1C65226E3D5513C4dosing.json
      /records/53/professional_sources/3/kind      		Historical; current review incomplete
      H51-99160DB021B6A7C95C0DDDECdosing.json
      /records/53/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-23E9306350202BBDE6C0745Cdosing.json
      /records/53/clinical_review/reviewed      		Historical; current review incomplete
      H51-B3E0B3D2394C03EA87BD7A3Ddosing.json
      /records/53/clinical_review/status      		Historical; current review incomplete
      H51-F14453174A20417F12C43270dosing.json
      /records/53/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-6B7540BC1341F2B38CB94FCBdosing.json
      /records/53/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-DF6BF12930DC10D19BEBB5A4dosing.json
      /records/53/clinical_release_verification/level      		Historical; current review incomplete
      H51-AE78D69CF73386E526694814dosing.json
      /records/53/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-1DCD7B887B493FDDF742269Adosing.json
      /records/53/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-0B01C352DB73C9828C3D8514dosing.json
      /records/53/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-1499495B9E85BF9D20E5D0FAdosing.json
      /records/53/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-4AB7588CB26D6F5D3A09D530dosing.json
      /records/53/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-736261C34403B26F032998C7dosing.json
      /records/53/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-AF5E5783BA3E217493226611dosing.json
      /records/53/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-420FCCB5672C797DDFF1CD61dosing.json
      /records/53/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-26B47639F251C70C236AB5B0dosing.json
      /records/53/clinical_release_verification/note      		Historical; current review incomplete
      H51-B72B1E27130E1BB6B128F735dosing.json
      /records/53/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-C5B3086502B454F999C5689Efirst-look-v5.1.json
      /records/53/id      		Historical; current review incomplete
      H51-9746F805A4A248FFFD4D03CBfirst-look-v5.1.json
      /records/53/generic_name      		Historical; current review incomplete
      H51-8CA8E1C44449805A00A92403first-look-v5.1.json
      /records/53/class      		Historical; current review incomplete
      H51-9E720BEDBCF63DBA91BCC7FAfirst-look-v5.1.json
      /records/53/subclass      		Historical; current review incomplete
      H51-F8B3D7B6371DA13BB3148AD7first-look-v5.1.json
      /records/53/primary_uses/0      		Historical; current review incomplete
      H51-A4636A5205B9CD685839D09Bfirst-look-v5.1.json
      /records/53/primary_uses/1      		Historical; current review incomplete
      H51-E424F831DE14295BE48E538Dfirst-look-v5.1.json
      /records/53/primary_uses/2      		Historical; current review incomplete
      H51-E2016618B0FF307638486015first-look-v5.1.json
      /records/53/mechanism      		Historical; current review incomplete
      H51-86BE0A26BB5A575724FF266Cfirst-look-v5.1.json
      /records/53/mechanism_level      		Historical; current review incomplete
      H51-0614849F1C3DD0229562B6C6first-look-v5.1.json
      /records/53/basic_dosing_orientation      		Historical; current review incomplete
      H51-D32F791CF88C8A4E0C7E49B7first-look-v5.1.json
      /records/53/administration_orientation      		Historical; current review incomplete
      H51-DE0A64EC6A5CE37D67E70E4Afirst-look-v5.1.json
      /records/53/renal_and_population_orientation      		Historical; current review incomplete
      H51-F40D1C3EBBDEEDB43E95EC83first-look-v5.1.json
      /records/53/key_safety_orientation/0      		Historical; current review incomplete
      H51-809408D877068707EEA59E24first-look-v5.1.json
      /records/53/key_safety_orientation/1      		Historical; current review incomplete
      H51-D23EA8F264711D04C5AB6E03first-look-v5.1.json
      /records/53/coverage_path      		Historical; current review incomplete
      H51-4318E48368C713CCAACB0789first-look-v5.1.json
      /records/53/coverage_path_label      		Historical; current review incomplete
      H51-1D8FEA8481496A4C7E8AA037first-look-v5.1.json
      /records/53/official_label_url      		Historical; current review incomplete
      H51-D1368A16527D73AE75FCDECCfirst-look-v5.1.json
      /records/53/legacy_title      		Historical; current review incomplete
      H51-930ADBEB2C671B5BC1531874first-look-v5.1.json
      /records/53/review_note      		Historical; current review incomplete
      H51-E4D865A47C28C5C87BFDDCFBfirst-look-v5.1.json
      /records/53/search_text      		Historical; current review incomplete
      H51-20A19189C488D2326900E258first-look-v5.1.json
      /records/53/official_search_url      		Historical; current review incomplete
      H51-E79D711A5997C47C693A75DDfirst-look-v5.1.json
      /records/53/official_access_mode      		Historical; current review incomplete
      H51-799334BD038D9BB3A25F97CBfirst-look-v5.1.json
      /records/53/official_access_url      		Historical; current review incomplete
      H51-47B87B7F5870768D09EC6FDBfirst-look-v5.1.json
      /records/53/official_search_query      		Historical; current review incomplete
      H51-314220AA3BA4E69A153E6207first-look-v5.1.json
      /records/53/official_access_reason      		Historical; current review incomplete
      H51-4762306AB422FE3CE9B44348first-look-v5.1.json
      /records/53/label_snapshot_available      		Historical; current review incomplete
      H51-99FFB4E24B15FE652051CF6Bfirst-look-v5.1.json
      /records/53/label_snapshot_setid      		Historical; current review incomplete
      H51-FD31CF11C00BFC45BB8011CEpreparation-assessments-v3.8.json
      /53/id      		Historical; current review incomplete
      H51-1BC1B33421306CF6FAA44FF0preparation-assessments-v3.8.json
      /53/name      		Historical; current review incomplete
      H51-14001F3B5B36B7CF80AC565Epreparation-assessments-v3.8.json
      /53/brands      		Historical; current review incomplete
      H51-FBFE271C7AD924F85449358Dpreparation-assessments-v3.8.json
      /53/therapeutic_class      		Historical; current review incomplete
      H51-6CEA747604CDC020FE6EF575preparation-assessments-v3.8.json
      /53/review_version      		Historical; current review incomplete
      H51-B5C1252B96BC9241E063EF0Bpreparation-assessments-v3.8.json
      /53/review_date      		Historical; current review incomplete
      H51-812A437E8AE4F9A0F1CE477Apreparation-assessments-v3.8.json
      /53/release_status      		Historical; current review incomplete
      H51-E89D8DB0F1F29AC6930A0165preparation-assessments-v3.8.json
      /53/market_status/status      		Historical; current review incomplete
      H51-27800A122907A030F4FECBF6preparation-assessments-v3.8.json
      /53/market_status/basis      		Historical; current review incomplete
      H51-E3AA55ED612E5CF6647C4249preparation-assessments-v3.8.json
      /53/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-4B3954D72ED4BECBB2D08085preparation-assessments-v3.8.json
      /53/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-F40A85F5556681A468BE2718preparation-assessments-v3.8.json
      /53/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-D9606A8A290C6969F9DE841Epreparation-assessments-v3.8.json
      /53/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-9B2EA0A329303B0B8604F4B0preparation-assessments-v3.8.json
      /53/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-FEDDF3E4E6D8CD4743CE889Apreparation-assessments-v3.8.json
      /53/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-F1FC3B0EC5664861BC331FE4preparation-assessments-v3.8.json
      /53/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-191387BB1BBEDE1439A6CE73preparation-assessments-v3.8.json
      /53/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-0426AAAA1B4E966766CE0372preparation-assessments-v3.8.json
      /53/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-EC4B7AF9E0A5FA4C9DF07B20preparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-B8F04D59F04DEC396C31B273preparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-F49AB0E51656E8F129D4A662preparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-162419118BF222AF13488F3Dpreparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-4F7F2920AE895736C642B0E6preparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-CFB8504F4C6BC85491EEECF0preparation-assessments-v3.8.json
      /53/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-B534D7EF58CB37238E2C1445preparation-assessments-v3.8.json
      /53/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-7679480E9BC66EB0E3CB76F7preparation-assessments-v3.8.json
      /53/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-F4E3075A5ECC87DAEBCF08A3preparation-assessments-v3.8.json
      /53/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-BD0D3C206A9D6254BB7B2EEBpreparation-assessments-v3.8.json
      /53/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-0586F7E6FAAB0CD8BF5158B5preparation-assessments-v3.8.json
      /53/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-7D6F54CFC0E4103578704B9Apreparation-assessments-v3.8.json
      /53/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-74D0127A488242E5FE9212A2preparation-assessments-v3.8.json
      /53/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-75A5323A74EEF80BA16DC3C8preparation-assessments-v3.8.json
      /53/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-0C2F7762AD4E6BA8AC49EAF2preparation-assessments-v3.8.json
      /53/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-3C2840DE2632E0DA83B39383preparation-assessments-v3.8.json
      /53/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-B1B8F909B020000866BD7DAApreparation-assessments-v3.8.json
      /53/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-CCFDBFC255822A6D4D099108preparation-assessments-v3.8.json
      /53/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-6B8B70037065A9C4435AC1FEpreparation-assessments-v3.8.json
      /53/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-7AFE525D41E419E66301D510preparation-assessments-v3.8.json
      /53/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-861D39044A12784CE35ECE2Fpreparation-assessments-v3.8.json
      /53/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-8FA31FCCD455B96FDEEBCF73preparation-assessments-v3.8.json
      /53/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-B158EDA72E2DD00474CA70C3preparation-assessments-v3.8.json
      /53/route_presence/structured_dilution      		Historical; current review incomplete
      H51-D847FD59E0C134F61C94A7E5preparation-assessments-v3.8.json
      /53/route_presence/iv_push      		Historical; current review incomplete
      H51-CDD57C9ED22E33FAEC1E533Cpreparation-assessments-v3.8.json
      /53/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-B78E2086E1775990FA4EEADEpreparation-assessments-v3.8.json
      /53/route_presence/pediatric_source      		Historical; current review incomplete
      H51-6B4B6C734A2B0A427B796974preparation-assessments-v3.8.json
      /53/route_presence/neonatal_source      		Historical; current review incomplete
      H51-3D0BCBA7D724258E37F3E257preparation-assessments-v3.8.json
      /53/legacy_reference/status      		Historical; current review incomplete
      H51-B4739B023A3657762AB149C9preparation-assessments-v3.8.json
      /53/label_resolution/status      		Historical; current review incomplete
      H51-CBA399F631FD123DC029028Cpreparation-assessments-v3.8.json
      /53/source_files/0      		Historical; current review incomplete
      H51-733FD5C67AAB1BF06B826E4Bpreparation-assessments-v3.8.json
      /53/source_files/1      		Historical; current review incomplete
      H51-D3B8978FCB38D3105EF4A8E2preparation-assessments-v3.8.json
      /53/source_files/2      		Historical; current review incomplete
      H51-5FAE7BE77E4355FB6874246Bpreparation-assessments-v3.8.json
      /53/source_files/3      		Historical; current review incomplete
      H51-2F0751AF30F1353CD318B214preparation-assessments-v3.8.json
      /53/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top